Skip to content

Allen & Overy advises Apax Partners and its portfolio company Neuraxpharm on the acquisition of Buccolam® Assets

Related people
Burns Paul
Paul Burns

Partner

New York

View profile →

Stuehler Dominik
Dominik Stühler

Partner

Munich

View profile →

Appleton Matthew
Matthew Appleton

Partner

London

View profile →

Ford Jim
Jim Ford

Partner

London

View profile →

Weber Heike
Dr Heike Weber

Partner

Frankfurt am Main

View profile →

Caitlin Hanley

Associate

New York

View profile →

Irving Gareth
Gareth Irving

Counsel

London

View profile →

Keren Livneh

Associate

New York

View profile →

Galle Rene
Dr Rene Galle

Counsel

Hamburg

View profile →

18 September 2020

We have advised Apax Partners and its portfolio company Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), on the acquisition of the assets and rights related to prescription brand Buccolam® from Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, in a multinational asset deal announced in September 2020. The transaction is expected to close by the end of 2020.

Buccolam® is a leading treatment for prolonged, acute, convulsive seizures (PACS) in infants, children and adolescents, with an extensive customer base across 18 countries in Europe and Israel.

Paul Burns, a partner in Allen & Overy’s Corporate and M&A practice, said: “This is an exciting acquisition for Neuraxpharm to expedite and expand access to this emergency treatment for epileptic children across regions. We’re proud of our work with our international teams, leveraging our global colleagues to benefit our clients.”

Allen & Overy’s cross border experience within the healthcare and pharmaceuticals space played an important role in this transaction, which will bring a critical and highly effective treatment to new markets. The U.S. Corporate and M&A practices worked alongside colleagues in the UK, Spain and Germany to address the cross-border complexities of this transaction. The Allen & Overy team has advised on multiple cross-border deals within the global healthcare and pharmaceuticals space in sub-sectors ranging from medicines and food supplements to cosmetics and medical devices, among others.

Dominik Stühler, a partner in Allen & Overy’s Private Equity practice in Munich, said: “This transaction required detailed understanding of regional healthcare regulations and cross-border M&A considerations, and I’m proud to work on a team that can deliver on all fronts.”

The Allen & Overy team advising Neuraxpharm Group was led by M&A partner Paul Burns, associates Caitlin Hanley and Lucy Cai in New York, supported by London-based Corporate partners Matthew Appleton and Jim Ford, counsel Gareth Irving, associates Megan McMellon, Ben Brooks, Magnus Yadi, associate Marta Guardiola in Madrid, and Private Equity partner Dominik Stühler and counsel Kai Terstiege in Munich. New York-based Senior Associate Keren Livneh advised on the IP aspects of the transaction, with Frankfurt-based partner Heike Weber and associate John Hibbard in New York counseling on Tax elements of the transaction. Hamburg-based counsel Rene Galle and associate Philipp Steinhaeuser delivered specialist Antitrust advice.